Manuscript Discussing The Benefit Of SeaStar Medical's Selective Cytopheretic Device In Patients With Heart Failure And Hyperinflammation Published In European Journal Of Heart Failure
Manuscript Discussing The Benefit Of SeaStar Medical's Selective Cytopheretic Device In Patients With Heart Failure And Hyperinflammation Published In European Journal Of Heart Failure
《歐洲心力衰竭雜誌》上發表的關於SeaStar Medical選擇性細胞移植設備對心力衰竭和炎症過度患者的益處的手稿
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients
人們對制定減少全身性炎症的新策略的興趣持續增長,以此作爲改善心力衰竭患者預後的一種手段
DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces publication of a manuscript discussing the role of chronic dysregulated systemic inflammation in heart failure and the potential application of the adult Selective Cytopheretic Device, part of the Quelimmune product family, in enabling previously ineligible patients with severe disease to receive a left ventricular assist device (LVAD) or heart transplant in...
丹佛,2024年2月27日(GLOBE NEWSWIRE)——開發專有解決方案以減少重要器官炎症後果的醫療器械公司SeaStar Medical Holdi...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。